Hemopoietic stem cell allogeneic transplantation (HSCT)using a reduced conditioning regimen: A single centre experience

Rosanna Scimè, Anna M. Cavallaro, Alessandra Santoro, Stefania Tringali, Alessandro Indovina, Raimondo Marcenö, Maria Pagano, Daniela Polizzi, Ignazio Majolino

Research output: Contribution to journalArticle

Abstract

Allogeneic transplantation is a potentially curative treatment for most hematological diseases, but its use is still associated with a high regimen related toxicity. Recently regimens with reduced toxicity have been employed.We report here our experience in 12 patients (7 male,5 female) with advanced hematological ( 11 ) or non-hematological(N=l)malignancies, who were treated with a non myeloablative regimen and sibling donor HLA compatible PBSC graft. Median age was 40 yfrange 14-62). Diagnoses were the following: 3 ALL, 2 AML, 2 HD, 1 CML, 1 MDS.l MM, 1 NHD.l breast cancer. Most have been heavly pretreated: 5 were previously allografted and 4 autografted. Disease status at transplant was: I PR, 6 relapses, 2 PD, 1 refractory, 2 CR. As conditioning nine pts received thiotepa (TT) 5 rag/kg and fludarabine (FAMP) 25 mg/m2 x 5 days, 2 patients received FAMP at the same dosage with Ara-C 2 g/m2 x 6 doses, 1 received TT 5 mg/kg and CY 100 mg/kg. All patients received unmanipulated PBSC with a median of 10.4 x 10e6/kg CD34+ (range 221.7). CSA alone 2.5 mg/kg was employed as GVHD prophylaxis. Median time with ANC

Original languageEnglish
JournalBlood
Volume96
Issue number11 PART II
Publication statusPublished - 2000

Fingerprint

Thiotepa
Homologous Transplantation
Stem Cell Transplantation
Stem cells
Toxicity
Emitter coupled logic circuits
Transplants
Cytarabine
Grafts
Refractory materials
Hematologic Diseases
Siblings
Tissue Donors
Breast Neoplasms
Recurrence
Conditioning (Psychology)
Neoplasms
Therapeutics
fludarabine

ASJC Scopus subject areas

  • Hematology

Cite this

Scimè, R., Cavallaro, A. M., Santoro, A., Tringali, S., Indovina, A., Marcenö, R., ... Majolino, I. (2000). Hemopoietic stem cell allogeneic transplantation (HSCT)using a reduced conditioning regimen: A single centre experience. Blood, 96(11 PART II).

Hemopoietic stem cell allogeneic transplantation (HSCT)using a reduced conditioning regimen : A single centre experience. / Scimè, Rosanna; Cavallaro, Anna M.; Santoro, Alessandra; Tringali, Stefania; Indovina, Alessandro; Marcenö, Raimondo; Pagano, Maria; Polizzi, Daniela; Majolino, Ignazio.

In: Blood, Vol. 96, No. 11 PART II, 2000.

Research output: Contribution to journalArticle

Scimè, R, Cavallaro, AM, Santoro, A, Tringali, S, Indovina, A, Marcenö, R, Pagano, M, Polizzi, D & Majolino, I 2000, 'Hemopoietic stem cell allogeneic transplantation (HSCT)using a reduced conditioning regimen: A single centre experience', Blood, vol. 96, no. 11 PART II.
Scimè R, Cavallaro AM, Santoro A, Tringali S, Indovina A, Marcenö R et al. Hemopoietic stem cell allogeneic transplantation (HSCT)using a reduced conditioning regimen: A single centre experience. Blood. 2000;96(11 PART II).
Scimè, Rosanna ; Cavallaro, Anna M. ; Santoro, Alessandra ; Tringali, Stefania ; Indovina, Alessandro ; Marcenö, Raimondo ; Pagano, Maria ; Polizzi, Daniela ; Majolino, Ignazio. / Hemopoietic stem cell allogeneic transplantation (HSCT)using a reduced conditioning regimen : A single centre experience. In: Blood. 2000 ; Vol. 96, No. 11 PART II.
@article{173dae54a66d47a6813ef8defc73d9f7,
title = "Hemopoietic stem cell allogeneic transplantation (HSCT)using a reduced conditioning regimen: A single centre experience",
abstract = "Allogeneic transplantation is a potentially curative treatment for most hematological diseases, but its use is still associated with a high regimen related toxicity. Recently regimens with reduced toxicity have been employed.We report here our experience in 12 patients (7 male,5 female) with advanced hematological ( 11 ) or non-hematological(N=l)malignancies, who were treated with a non myeloablative regimen and sibling donor HLA compatible PBSC graft. Median age was 40 yfrange 14-62). Diagnoses were the following: 3 ALL, 2 AML, 2 HD, 1 CML, 1 MDS.l MM, 1 NHD.l breast cancer. Most have been heavly pretreated: 5 were previously allografted and 4 autografted. Disease status at transplant was: I PR, 6 relapses, 2 PD, 1 refractory, 2 CR. As conditioning nine pts received thiotepa (TT) 5 rag/kg and fludarabine (FAMP) 25 mg/m2 x 5 days, 2 patients received FAMP at the same dosage with Ara-C 2 g/m2 x 6 doses, 1 received TT 5 mg/kg and CY 100 mg/kg. All patients received unmanipulated PBSC with a median of 10.4 x 10e6/kg CD34+ (range 221.7). CSA alone 2.5 mg/kg was employed as GVHD prophylaxis. Median time with ANC",
author = "Rosanna Scim{\`e} and Cavallaro, {Anna M.} and Alessandra Santoro and Stefania Tringali and Alessandro Indovina and Raimondo Marcen{\"o} and Maria Pagano and Daniela Polizzi and Ignazio Majolino",
year = "2000",
language = "English",
volume = "96",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11 PART II",

}

TY - JOUR

T1 - Hemopoietic stem cell allogeneic transplantation (HSCT)using a reduced conditioning regimen

T2 - A single centre experience

AU - Scimè, Rosanna

AU - Cavallaro, Anna M.

AU - Santoro, Alessandra

AU - Tringali, Stefania

AU - Indovina, Alessandro

AU - Marcenö, Raimondo

AU - Pagano, Maria

AU - Polizzi, Daniela

AU - Majolino, Ignazio

PY - 2000

Y1 - 2000

N2 - Allogeneic transplantation is a potentially curative treatment for most hematological diseases, but its use is still associated with a high regimen related toxicity. Recently regimens with reduced toxicity have been employed.We report here our experience in 12 patients (7 male,5 female) with advanced hematological ( 11 ) or non-hematological(N=l)malignancies, who were treated with a non myeloablative regimen and sibling donor HLA compatible PBSC graft. Median age was 40 yfrange 14-62). Diagnoses were the following: 3 ALL, 2 AML, 2 HD, 1 CML, 1 MDS.l MM, 1 NHD.l breast cancer. Most have been heavly pretreated: 5 were previously allografted and 4 autografted. Disease status at transplant was: I PR, 6 relapses, 2 PD, 1 refractory, 2 CR. As conditioning nine pts received thiotepa (TT) 5 rag/kg and fludarabine (FAMP) 25 mg/m2 x 5 days, 2 patients received FAMP at the same dosage with Ara-C 2 g/m2 x 6 doses, 1 received TT 5 mg/kg and CY 100 mg/kg. All patients received unmanipulated PBSC with a median of 10.4 x 10e6/kg CD34+ (range 221.7). CSA alone 2.5 mg/kg was employed as GVHD prophylaxis. Median time with ANC

AB - Allogeneic transplantation is a potentially curative treatment for most hematological diseases, but its use is still associated with a high regimen related toxicity. Recently regimens with reduced toxicity have been employed.We report here our experience in 12 patients (7 male,5 female) with advanced hematological ( 11 ) or non-hematological(N=l)malignancies, who were treated with a non myeloablative regimen and sibling donor HLA compatible PBSC graft. Median age was 40 yfrange 14-62). Diagnoses were the following: 3 ALL, 2 AML, 2 HD, 1 CML, 1 MDS.l MM, 1 NHD.l breast cancer. Most have been heavly pretreated: 5 were previously allografted and 4 autografted. Disease status at transplant was: I PR, 6 relapses, 2 PD, 1 refractory, 2 CR. As conditioning nine pts received thiotepa (TT) 5 rag/kg and fludarabine (FAMP) 25 mg/m2 x 5 days, 2 patients received FAMP at the same dosage with Ara-C 2 g/m2 x 6 doses, 1 received TT 5 mg/kg and CY 100 mg/kg. All patients received unmanipulated PBSC with a median of 10.4 x 10e6/kg CD34+ (range 221.7). CSA alone 2.5 mg/kg was employed as GVHD prophylaxis. Median time with ANC

UR - http://www.scopus.com/inward/record.url?scp=33748523132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748523132&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748523132

VL - 96

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11 PART II

ER -